Table 1.
Characteristics of patients enrolled on COG ANBL0931 (n = 105).
| Age, years | |
| Median | 4.1 |
| Range | 1.1–27.5 |
| Sex | |
| Male | 59 (56.2%) |
| Female | 46 (43.8%) |
| Race | |
| White | 82 (78.1%) |
| Black | 10 (9.5%) |
| Other | 13 (12.4%) |
| Ethnicity | |
| Hispanic | 9 (8.6%) |
| Other | 96 (91.4%) |
| Histology | |
| Favorable | 4 (5.5%) |
| Unfavorable | 69 (94.5%) |
| Unknown | 32 |
| INSS stage | |
| Stage 1a | 2 (2.5%) |
| Stage 2b | 1 (1.2%) |
| Stage 3 | 15 (18.5%) |
| Stage 4 | 63 (77.8%) |
| Unknown | 24 |
| MYCN status | |
| Non-amplified | 40 (57.1%) |
| Amplified | 30 (42.9%) |
| Unknown | 35 |
| Number of ASCTs prior to study | |
| One | 88 (83.8%) |
| Two | 17 (16.2%) |
| Disease status at study entry | |
| Complete response | 29 (27.6%) |
| Very good partial response (PR) | 36 (34.3%) |
| PR | 40 (38.1%) |
aMYCN amplified tumor (n = 1), progression to metastatic disease meeting high-risk criteria during follow-up (n = 1).
bMYCN amplified tumor.